Joel H. Collier

Joel H. Collier

Auto-generated profile, based on publicly available information

Joel H. Collier

Department of Biomedical Engineering, Duke University, Durham, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JRJai S. Rudra
Jai S. Rudra
YTYe F. Tian
Ye F. Tian
JJJangwook P. Jung
Jangwook P. Jung
JCJoel H. Collier
Joel H. Collier
The development of vaccines and other immunotherapies has been complicated by heterogeneous antigen display and the use of incompletely defined immune adjuvants with complex mechanisms of action. We have observed strong antibody responses in mice without the coadministration of any additional adjuvant by noncovalently assembling a T and B cell epitope peptide into nanofibers using a short C-terminal peptide extension. Self-assembling peptides have been explored recently as scaffolds for tissue engineering and regenerative medicine, but our results indicate that these materials may also be useful as chemically defined adjuvants. In physiological conditions, these peptides self-assembled into long, unbranched fibrils that displayed the epitope on their surfaces. IgG1, IgG2a, and IgG3 were raised against epitope-bearing fibrils in levels similar to the epitope peptide delivered in complete Freund’s adjuvant (CFA), and IgM production was even greater for the self-assembled epitope. This response was dependent on self-assembly, and the self-assembling sequence was not immunogenic by itself, even when delivered in CFA. Undetectable levels of interferon-gamma, IL-2, and IL-4 in cultures of peptide-challenged splenocytes from immunized mice suggested that the antibody responses did not involve significant T cell help.

24 January 2012 in ACS Nano
Verified
Journal Article
Closed access
JRJai S. Rudra
Jai S. Rudra
TSTao Sun
Tao Sun
KBKatelyn C. Bird
Katelyn C. Bird
MDMelvin D. Daniels
Melvin D. Daniels
JGJoshua Z. Gasiorowski
Joshua Z. Gasiorowski
JCJoel H. Collier
Joel H. Collier

15 June 2014 in Nature Materials
Verified
Journal Article
Open access
PDF file
GHGregory A. Hudalla
Gregory A. Hudalla
TSTao Sun
Tao Sun
JGJoshua Z. Gasiorowski
Joshua Z. Gasiorowski
HHHuifang Han
Huifang Han
YTYe F. Tian
Ye F. Tian
JCJoel H. Collier
Joel H. Collier
Biomaterials exhibiting precise ratios of different bioactive protein components are critical for applications ranging from vaccines to regenerative medicine, but their design is often hindered by limited choices and cross-reactivity of protein conjugation chemistries. Here, we describe a strategy for inducing multiple different expressed proteins of choice to assemble into nanofibres and gels with exceptional compositional control. The strategy employs ‘βTail’ tags, which allow for good protein expression in bacteriological cultures, yet can be induced to co-assemble into nanomaterials when mixed with additional β-sheet fibrillizing peptides. Multiple different βTail fusion proteins could be inserted into peptide nanofibres alone or in combination at predictable, smoothly gradated concentrations, providing a simple yet versatile route to install precise combinations of proteins into nanomaterials. The technology is illustrated by achieving precisely targeted hues using mixtures of fluorescent proteins, by creating nanofibres bearing enzymatic activity, and by adjusting antigenic dominance in vaccines.

1 June 2011 in Biomaterials
Verified
Journal Article
Closed access
JCJoel H. Collier
Joel H. Collier
TSTatiana Segura
Tatiana Segura

17 August 2020 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
CFChelsea N. Fries
Chelsea N. Fries
ECElizabeth J. Curvino
Elizabeth J. Curvino
JCJui-Lin Chen
Jui-Lin Chen
SPSallie Permar
Sallie Permar
GFGenevieve G. Fouda
Genevieve G. Fouda
JCJoel H. Collier
Joel H. Collier
Despite the overwhelming success of vaccines in preventing infectious diseases, there remain numerous globally devastating diseases without fully protective vaccines, particularly human immunodeficiency virus (HIV), malaria and tuberculosis. Nanotechnology approaches are being developed both to design new vaccines against these diseases as well as to facilitate their global implementation. The reasons why a given pathogen may present difficulties for vaccine design are unique and tied to the co-evolutionary history of the pathogen and humans, but there are common challenges that nanotechnology is beginning to help address. In each case, a successful vaccine will need to raise immune responses that differ from the immune responses raised by normal infection. Nanomaterials, with their defined compositions, commonly modular construction, and length scales allowing the engagement of key immune pathways, collectively facilitate the iterative design process necessary to identify such protective immune responses and achieve them reliably. Nanomaterials also provide strategies for engineering the trafficking and delivery of vaccine components to key immune cells and lymphoid tissues, and they can be highly multivalent, improving their engagement with the immune system. This Review will discuss these aspects along with recent nanomaterial advances towards vaccines against infectious disease, with a particular emphasis on HIV/AIDS, malaria and tuberculosis.

5 July 2010 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
JCJoel H. Collier
Joel H. Collier
JRJai S. Rudra
Jai S. Rudra
JGJoshua Z. Gasiorowski
Joshua Z. Gasiorowski
JJJangwook P. Jung
Jangwook P. Jung
Extracellular matrices (ECMs) are challenging design targets for materials synthesis because they serve multiple biological roles, and they are composed of multiple molecular constituents. In addition, their composition and activities are dynamic and variable between tissues, and they are difficult to study mechanistically in physiological contexts. Nevertheless, the design of synthetic ECMs is a central consideration in applications such as regenerative medicine and 3D cell culture. In order to produce synthetic matrices having both multi-component construction and high levels of compositional definition, strategies based on molecular self-assembly are receiving increasing interest. These approaches are described in this tutorial review and compared with the structures and processes in native ECMs that serve as their inspiration.